Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dostarlimab · Jemperli, TSR-042

Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Glaxosmithkline

Approved FDA, Apr 2021
GSK Developer
2 Registered trials

What is Dostarlimab?

Dostarlimab is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1-mediated suppression of anti-tumor immunity. It is studied in cervical cancer, advanced cancer and ovarian clear cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Jemperli, TSR-042, GSK-4057190
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1)
Mechanism
Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation
Therapy area
Oncology
Developer
Glaxosmithkline (GSK)
FDA status
Approved as Jemperli (April 22, 2021), BLA761174 · FDA label
UNII
P0GVQ9A4S5

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 2, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06065462 Phase 1/2 Ovarian Clear Cell Carcinoma Recruiting GSK
NCT03833479 Phase 2 Cervical Cancer Active not recruiting GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerCervical CancerOvarian Clear Cell Carcinoma

Other drugs acting on PDCD1

More from Glaxosmithkline

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind Dostarlimab

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.